Prominent publications by Charles M Perou

KOL Index score: 19600

BACKGROUND: Pathological complete response has been proposed as a surrogate endpoint for prediction of long-term clinical benefit, such as disease-free survival, event-free survival (EFS), and overall survival (OS). We had four key objectives: to establish the association between pathological complete response and EFS and OS, to establish the definition of pathological complete response that correlates best with long-term outcome, to identify the breast cancer subtypes in which ...

Also Ranks for: Pathological Complete Response |  ypt0 ypn0 ypt0 |  pooled analysis |  breast chemotherapy |  surrogate endpoint
KOL Index score: 18920

PURPOSE: One third of patients with triple-negative breast cancer (TNBC) achieve pathologic complete response (pCR) with standard neoadjuvant chemotherapy (NACT). CALGB 40603 (Alliance), a 2 × 2 factorial, open-label, randomized phase II trial, evaluated the impact of adding carboplatin and/or bevacizumab.

PATIENTS AND METHODS: Patients (N = 443) with stage II to III TNBC received paclitaxel 80 mg/m(2) once per week (wP) for 12 weeks, followed by doxorubicin plus cyclophosphamide once ...

Also Ranks for: Carboplatin Bevacizumab |  pathologic complete response |  pcr breast |  iii triple |  calgb 40603
KOL Index score: 17818

BACKGROUND: Gene expression profiling of breast cancer has identified two biologically distinct estrogen receptor (ER)-positive subtypes of breast cancer: luminal A and luminal B. Luminal B tumors have higher proliferation and poorer prognosis than luminal A tumors. In this study, we developed a clinically practical immunohistochemistry assay to distinguish luminal B from luminal A tumors and investigated its ability to separate tumors according to breast cancer recurrence-free and ...

Also Ranks for: Her2 Status |  breast cancer luminal |  neoplastic humans |  gene expression profiling |  estrogen receptors
KOL Index score: 15647

Importance: African Americans have the highest breast cancer mortality rate. Although racial difference in the distribution of intrinsic subtypes of breast cancer is known, it is unclear if there are other inherent genomic differences that contribute to the survival disparities.

Objectives: To investigate racial differences in breast cancer molecular features and survival and to estimate the heritability of breast cancer subtypes.

Design, Setting, and Participants: Among a convenience ...

Also Ranks for: Breast Cancer |  european ancestry |  molecular features |  genome atlas |  african americans
KOL Index score: 15182

PURPOSE: Dual human epidermal growth factor receptor 2 (HER2) targeting can increase pathologic complete response rates (pCRs) to neoadjuvant therapy and improve progression-free survival in metastatic disease. CALGB 40601 examined the impact of dual HER2 blockade consisting of trastuzumab and lapatinib added to paclitaxel, considering tumor and microenvironment molecular features.

PATIENTS AND METHODS: Patients with stage II to III HER2-positive breast cancer underwent tumor biopsy ...

Also Ranks for: Molecular Heterogeneity |  estrogen receptors |  trastuzumab lapatinib |  pcr rates |  epidermal growth
KOL Index score: 15130

PURPOSE: FOXA1, a forkhead family transcription factor, is essential for optimum expression of approximately 50% of estrogen receptor alpha (ERalpha):estrogen responsive genes. FOXA1 is expressed in breast cancer cells. It segregates with genes that characterize the luminal subtypes in DNA microarray analyses. The utility of FOXA1 as a possible independent prognostic factor has not been determined in breast cancers.

MATERIALS AND METHODS: A tissue microarray comprising tumors from 438 ...

Also Ranks for: Foxa1 Expression |  luminal subtype |  breast cancer |  estrogen receptors |  nodal status
KOL Index score: 14922

CONTEXT: Gene expression analysis has identified several breast cancer subtypes, including basal-like, human epidermal growth factor receptor-2 positive/estrogen receptor negative (HER2+/ER-), luminal A, and luminal B.

OBJECTIVES: To determine population-based distributions and clinical associations for breast cancer subtypes.

DESIGN, SETTING, AND PARTICIPANTS: Immunohistochemical surrogates for each subtype were applied to 496 incident cases of invasive breast cancer from the Carolina ...

Also Ranks for: Breast Cancer |  her2 luminal |  higher prevalence |  estrogen receptors |  basal subtypes
KOL Index score: 14699

BACKGROUND: Many methodologies have been used in research to identify the "intrinsic" subtypes of breast cancer commonly known as Luminal A, Luminal B, HER2-Enriched (HER2-E) and Basal-like. The PAM50 gene set is often used for gene expression-based subtyping; however, surrogate subtyping using panels of immunohistochemical (IHC) markers are still widely used clinically. Discrepancies between these methods may lead to different treatment decisions.

METHODS: We used the PAM50 RT-qPCR ...

Also Ranks for: Breast Cancer |  luminal her2 |  gene expression |  esr1 pgr |  estrogen receptor
KOL Index score: 13703

BACKGROUND: Diffuse low-grade and intermediate-grade gliomas (which together make up the lower-grade gliomas, World Health Organization grades II and III) have highly variable clinical behavior that is not adequately predicted on the basis of histologic class. Some are indolent; others quickly progress to glioblastoma. The uncertainty is compounded by interobserver variability in histologic diagnosis. Mutations in IDH, TP53, and ATRX and codeletion of chromosome arms 1p and 19q (1p/19q ...

Also Ranks for: Grade Gliomas |  mutations idh |  1p 19q codeletion |  integrative genomic analysis |  diffuse lower
KOL Index score: 13691

Both abundant epidermal growth factor receptor (EGFR or ErbB1) and high activity of the phosphatidylinositol 3-kinase (PI3K)-Akt pathway are common and therapeutically targeted in triple-negative breast cancer (TNBC). However, activation of another EGFR family member [human epidermal growth factor receptor 3 (HER3) (or ErbB3)] may limit the antitumor effects of these drugs. We found that TNBC cell lines cultured with the EGFR or HER3 ligand EGF or heregulin, respectively, and treated ...

Also Ranks for: Egfr Her3 |  negative breast |  akt pathway |  tnbc cell lines |  epidermal growth
KOL Index score: 13139

Targeting the dysregulated BRAF-MEK-ERK pathway in cancer has increasingly emerged in clinical trial design. Despite clinical responses in specific cancers using inhibitors targeting BRAF and MEK, resistance develops often involving nongenomic adaptive bypass mechanisms. Inhibition of MEK1/2 by trametinib in patients with triple-negative breast cancer (TNBC) induced dramatic transcriptional responses, including upregulation of receptor tyrosine kinases (RTK) comparing tumor samples ...

Also Ranks for: Mek Inhibition |  enhancer remodeling |  pharmacologic targeting |  antineoplastic agents |  preclinical models
KOL Index score: 13064

BACKGROUND: Although numerous mouse models of breast carcinomas have been developed, we do not know the extent to which any faithfully represent clinically significant human phenotypes. To address this need, we characterized mammary tumor gene expression profiles from 13 different murine models using DNA microarrays and compared the resulting data to those from human breast tumors.

RESULTS: Unsupervised hierarchical clustering analysis showed that six models (TgWAP-Myc, TgMMTV-Neu, ...

Also Ranks for: Human Breast Tumors |  gene expression |  murine mammary |  models breast |  estrogen receptor
KOL Index score: 12979

Microarray profiling of invasive breast carcinomas has identified five distinct subtypes of tumors (luminal A, luminal B, normal breast-like, HER2 overexpressing, and basal-like) that are associated with different clinical outcomes. The basal-like subtype is associated with poor clinical outcomes and is the subtype observed in BRCA1-related breast cancers. The aim of this study was to characterize the histologic and immunophenotypic properties of breast basal-like carcinomas that were ...

Also Ranks for: Basallike Tumors |  invasive breast carcinoma |  her2 egfr |  myoepithelial markers |  breast basal
KOL Index score: 12945

Metaplastic breast cancers (MBC) are aggressive, chemoresistant tumors characterized by lineage plasticity. To advance understanding of their pathogenesis and relatedness to other breast cancer subtypes, 28 MBCs were compared with common breast cancers using comparative genomic hybridization, transcriptional profiling, and reverse-phase protein arrays and by sequencing for common breast cancer mutations. MBCs showed unique DNA copy number aberrations compared with common breast cancers. ...

Also Ranks for: Stem Cell |  oncogene proteins |  breast cancer |  pik3ca mutations |  transcriptional profiling
KOL Index score: 12772

INTRODUCTION: Molecular subtyping of lung adenocarcinoma (AD) and lung squamous cell carcinoma (SCC) reveal biologically diverse tumors that vary in their genomic and clinical attributes.

METHODS: Published immune cell signatures and several lung AD and SCC gene expression data sets, including The Cancer Genome Atlas, were used to examine immune response in relation to AD and SCC expression subtypes. Expression of immune cell populations and other immune related genes, including CD274 ...

Also Ranks for: Expression Subtypes |  tumor immune |  lung adenocarcinoma |  cell carcinoma |  terminal respiratory unit

Key People For Breast Cancer

Top KOLs in the world
Ahmedin * *****
united states breast cancer addis ababa
Gabriel * **********
breast cancer neoadjuvant chemotherapy estrogen receptors
Rebecca * ******
united states colorectal cancer incidence rates
Charles * *****
breast cancer gene expression intrinsic subtypes
Freddie *** ****
cancer incidence nordic countries mortality rates
Jacques ******
cancer incidence global burden latin america

Charles M Perou:Expert Impact

Concepts for whichCharles M Perouhas direct influence:Breast cancer,  Gene expression,  Intrinsic subtypes,  Estrogen receptor,  Estrogen receptors,  Intrinsic subtype,  Breast cancers,  Cell lines.

Charles M Perou:KOL impact

Concepts related to the work of other authors for whichfor which Charles M Perou has influence:Breast cancer,  Gene expression,  Neoadjuvant chemotherapy,  Dna methylation,  Estrogen receptor,  Cell lines,  Molecular subtypes.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina | Department of Genetics, University of North Carolina, Chapel Hill, NC. | Department of Genetics, Lineberger Comprehensive Cancer Center, University of